Mark A. Berman - 01 Apr 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role
Chief Medical Officer
Signature
/s/ Mark Heinen, Attorney-in-Fact
Issuer symbol
BTTX on OTC
Transactions as of
01 Apr 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 16:43:59 UTC
Previous filing
01 Nov 2021
Next filing
21 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Award $0 +116,700 $0.000000 116,700 01 Apr 2022 Common Stock 116,700 $1.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.